INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2020-08-26
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of c-Met inhibitor INCB028060 and
erlotinib hydrochloride when given together in treating patients with previously treated
non-small cell lung cancer. C-Met inhibitor INCB028060 and erlotinib hydrochloride may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 1
Details
Lead Sponsor:
University of California, Davis
Collaborators:
National Cancer Institute (NCI) Novartis Pharmaceuticals